References of DNA,d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A),5',5''',5''''',5'''''''-[[1,2-ethanediylbis[oxy-2,1-ethanediyloxycarbonylnitrilobis[2,1-ethanediylimino(6-oxo-6,1-hexanediyl)imino(2-oxo-2,1-ethanediyl)thio-6,1-hexanediyl]]]tetrakis(hydrogen phosphate)], complex with DNAd(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) (1:4), hexapentacontahectasodiumsalt
Title: Abetimus Sodium
CAS Registry Number: 169147-32-4
CAS Name: d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)-DNA 5￠-ester with 1,2-ethanediylbis(oxy-2,1-ethanediyl) bis[2-(21,21-dihydroxy-21-oxido-4,11-dioxo-20-oxa-13-thia-3,10-diaza-21-phophaheneicos-1-yl)-23,23-dihydroxy-23-oxido-6,13-dioxo-22-oxa-15-thia-2,5,12-triaza-23-phosphatricosanoate] (4:1) complex with d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G)-DNA (1:1) hexapentacontahectasodium salt
Manufacturers' Codes: LJP-394
Trademarks: Riquent (La Jolla Pharmaceuticals)
Literature References: B-cell toleragen which prevents the expression of anti-ds-DNA. Consists of four identical ds-DNA oligonucleotides (20 basepairs) attached through a linker to a non-immunogenic modified triethylene glycol base. Relative mass of 54 kDa. Prepn: S. M. Coutts
et al., EP 642798;
eidem, US 5552391 (1995, 1996 both to La Jolla Pharm.); D. S. Jones
et al., J. Med. Chem. 38, 2138 (1995). Clinical evaluation in systemic lupus erythematosus (SLE): R. A. Furie
et al., J. Rheumatol. 28, 257 (2001); in prevention of SLE renal flare: D. Alarcon-Segovia
et al., Arthritis Rheum. 48, 442 (2003). Review of clinical pharmacology: D. J. Wallace,
Expert Opin. Invest. Drugs 10, 111-117 (2001); of clinical experience: M. H. Cardiel,
ibid. 14, 77-88 (2005).
Properties: Colorless aqueous solution with an osmolality of 255-310 mmol/kg at pH 6.8-7.8.
Therap-Cat: Immunosuppressant in treatment of SLE and associated nephritis.
Keywords: Immunosuppressant.
